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Mental health probiem is one of the problems in modern societies. mental disorders u itir
direct and indirect costs. has detrimental effects on society. Ir4anic depressive (bipolar
depression and mental illness are common in modern societies. N4anic depressive iilness.
is a mood disorder that is difficult to treat and responds. For the treatment of manic
depressive, multiple drug use has beneficial effects. Oral capsules of fluoxetine anC
olanzapine u,ith brand name S1,mb1.ax6 is available in the pharmaceutical market in the
u,orld, u,hich is a mixture of an at-vpical antips-vchotic drugs (olanzapine), an antidepressant
SSRI (fluoxetine) is used for the treatment of refractory bipolar disorder. This product is
not available in the lranian Pharmaceutical market, the aim of this study is to design and
manufacture the capsule formulation of fluoxetine-olanzapine and its investigation
physicochemical properties and stabilitv and finally offers better formulation"
Methods:
The design and selection of formulations is done, according to existing formulas in the
sources and bring about the changes, which are contain differnt combinations of active
pharmaceutical ingredients and excipients. Excipients used in these formulations are
include pre gelatinized starch, gelatin, crospovidone, sodium lauryl sulfate, lactose and
magnesium stearate. For this purpose, the amount of olanzapine and fluoxetine in all
formulas has been fixed, but the amount of excipients in the formulation is different' Five
different formulations were developed. After mixing and granulation of powders,
powders was filled inside capsules with size 3, then capsules of each formulation bacth
was divided into 3 parts. And in terms of temperature was kept at 1,,7, 4,8 and 24 weeks
to test the stability of the formulation at room temperature, the refrigerator and the
temperature of 40 " C. ln addition, the dissolution parameters, uniformity of weight, and
content uniformity of capsules was evaluated and the derivative spectrophotometry





Acording to result of this study, the formulation No. 2 has a better profile in terms of
physicochemical features and stability which is contains 25 mg of fluoxetine, 12 mg of
olanzapine, 5 mg of corn starch, 63.14 mg of pre gelatinized starch, 40mg of lactose 20mg
of sodium lauryl, 10 mg of crospovidone and 2 mg of magnesium stearate
Conclusions:
Formula (2) as the best formulation according to the results of its parametei's and the best
conditions for this product is stored at refrigerator temperature, after completion of
clinicalstudies on these products can be used for manufacturing produets of this formula.
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